UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Journal for immunotherapy of cancer, 2019-12, Vol.7 (1), p.354-20, Article 354

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

Journal for immunotherapy of cancer, 2019-12, Vol.7 (1), p.353-353, Article 353

2019

Link zum Volltext

Verfügbarkeit prüfen

Strategies for improving the management of immune-related adverse events

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001754

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Journal for immunotherapy of cancer, 2018-01, Vol.6 (1), p.9-9, Article 9

2018

Link zum Volltext

Verfügbarkeit prüfen

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

Journal for immunotherapy of cancer, 2023-03, Vol.11 (3), p.e006361

2023

Link zum Volltext

Verfügbarkeit prüfen

A case of checkpoint inhibitor-induced celiac disease

Journal for immunotherapy of cancer, 2019-08, Vol.7 (1), p.203-203, Article 203

2019

Link zum Volltext

Verfügbarkeit prüfen

The promise of Immuno-oncology: implications for defining the value of cancer treatment

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.129-129, Article 129

2019

Link zum Volltext

Verfügbarkeit prüfen

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

Journal for immunotherapy of cancer, 2023-03, Vol.11 (3), p.e006398

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for immunotherapy of cancer, 2024-04, Vol.12 (4)

2024

Link zum Volltext

Verfügbarkeit prüfen

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e002955

2021

Link zum Volltext

Verfügbarkeit prüfen

Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy

Journal for immunotherapy of cancer, 2020-05, Vol.8 (1), p.e000898

2020

Link zum Volltext

Verfügbarkeit prüfen

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

Journal for immunotherapy of cancer, 2023-03, Vol.11 (3), p.e005923

2023

Link zum Volltext

Verfügbarkeit prüfen

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective

Journal for immunotherapy of cancer, 2020-07, Vol.8 (2), p.e000648

2020

Link zum Volltext

Verfügbarkeit prüfen

Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors

Journal for immunotherapy of cancer, 2019-03, Vol.7 (1), p.61-61, Article 61

2019

Link zum Volltext

Verfügbarkeit prüfen

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003743

2021

Link zum Volltext

Verfügbarkeit prüfen

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs

Journal for immunotherapy of cancer, 2023-05, Vol.11 (5), p.e006555

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Journal for immunotherapy of cancer, 2023-03, Vol.11 (3), p.e004780

2023

Link zum Volltext

Verfügbarkeit prüfen

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)

Journal for immunotherapy of cancer, 2022-09, Vol.10 (9), p.e005413

2022

Link zum Volltext

Verfügbarkeit prüfen

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

Journal for immunotherapy of cancer, 2018-05, Vol.6 (1), p.44-44, Article 44

2018

Link zum Volltext

Verfügbarkeit prüfen

Evolving impact of long-term survival results on metastatic melanoma treatment

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e000948

2020

Link zum Volltext

Verfügbarkeit prüfen

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

Journal for Immunotherapy of Cancer, 2014-09, Vol.2 (1), p.26-26, Article 26

2014

Link zum Volltext

Verfügbarkeit prüfen

1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1125-A1125

2023

Link zum Volltext

Verfügbarkeit prüfen

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting

Journal for immunotherapy of cancer, 2017-04, Vol.5 (1), p.1-10, Article 38

2017

Link zum Volltext

Verfügbarkeit prüfen

1317 Enhancing patient safety in melanoma treatment: harnessing machine learning for predicting immune-related adverse events

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1468-A1468

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal For Immunotherapy Of Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

Strategies for improving the management of immune-related adverse events

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

A case of checkpoint inhibitor-induced celiac disease

The promise of Immuno-oncology: implications for defining the value of cancer treatment

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma

Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective

Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

Evolving impact of long-term survival results on metastatic melanoma treatment

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting

1317 Enhancing patient safety in melanoma treatment: harnessing machine learning for predicting immune-related adverse events

Aktive Filter

Suchergebnisse filtern